Given that the SUCNR1 receptor is considered a potential target for NAFLD therapy, more studies are needed to elucidate the regulation of SUCNR1 expression and the complex implications of its activation. Here, SUCNR1 is linked to metabolic dysfunction-associated steatotic liver disease.